Tag: Merck
Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as...
Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle Genetics/Astellas Pharma) in combination with...
Three U.S. Companies Awarded MilliporeSigma’s Advance Biotech Grant
MilliporeSigma Awards Grants to Biotechs Focused on Traumatic Brain Injury, Vaccine Development and Chronic Pain.
MilliporeSigma today announced the winners of its Advance Biotech Grant program...
Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...
Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...
Sutro Collaborates with Merck and Recombinant Antibody Network
Earlier today, Sutro Biopharma, Inc, a biopharmaceutical company located in South San Francisco developing antibody drug conjugates and bispecific antibodies for targeted cancer therapies, and Merck Serono, the biopharmaceutical division of Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono in the United States and Canada, announced that they will collaborate in developing Antibody-drug Conjugates or ADCs.
